SCHEMBL4850191

SCHEMBL4850191

CCCC12CCc3cc(O)ccc3C1=C(C)C(=O)C2

nearest known ligand 0.82

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 19/20 0.82
ESR1 P03372 19/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4850298 0.93 ESR2 (0.83) ESR2ESR1
SCHEMBL2417689 0.90 ESR2 (1.00) ESR2ESR1
SCHEMBL4859137 0.90 ESR2 (0.81) ESR2ESR1
SCHEMBL4856461 0.87 ESR2 (0.83) ESR2ESR1
SCHEMBL2415354 0.83 ESR2 (1.00) ESR2ESR1
SCHEMBL4850382 0.80 ESR2 (0.83) ESR2ESR1
SCHEMBL2420036 0.80 ESR2 (1.00) ESR2ESR1
SCHEMBL2414632 0.80 ESR2 (0.80) ESR2ESR1
SCHEMBL4858732 0.79 ESR2 (0.87) ESR2ESR1
SCHEMBL4858834 0.78 ESR2 (0.80) ESR2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7432284-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2008-10-07 US claimed
US-20060041003-A1 Estrogen receptor modulators MERCK SHARP & DOHME LLC 2006-02-23 US claimed
US-7432284-B2 Estrogen receptor modulators MERCK & CO., INC. (US) 2008-10-07 US disclosed
US-20060041003-A1 Estrogen receptor modulators MERCK SHARP & DOHME LLC 2006-02-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060041003-A1 Estrogen receptor modulators GPER1, ESR2, ESR1 ESR2 2/4885ESR1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.